Healthcare >> CEO Interviews >> September 13, 2002
KENNETH C. CARTER, PhD, is the President & CEO of Avalon
Pharmaceuticals, a genomics-based company utilizing unique and
proprietary methods to accelerate the drug discovery process. He has a
PhD in Human Genetics and Cell Biology as well as an extensive
background in both academic and corporate scientific settings. As a co-
founder and CEO of Avalon, Dr. Carter has overseen the company's rapid
development of genomics-based drug discovery approaches. Since opening
its doors in January 2000, the company has established several
partnerships and has received exceptional backing from the investment
community. From 1993-1998, Dr. Carter was at Human Genome Sciences,
Inc., where he directed the company's gene mapping initiative. In this
capacity, he played a direct role in the discovery, cloning, and
chromosomal mapping of dozens of new human genes. As a member of a team
of collaborating scientists from Human Genome Sciences and Johns Hopkins
University, Dr. Carter helped identify a family of genes involved in
colon cancer. In 1994, this finding was named 'Discovery of the Year' by
Science. Dr. Carter has more than 50 published scientific articles and
multiple patents. Profile
Pharmaceuticals does?
Dr. Carter: Avalon is a privately-held research and development company
focused on using genomic techniques
